Metronidazole Fresenius

Metronidazole, the active ingredient in Metronidazole Fresenius, is a nitroimidazole antibiotic presented as an injection for intravenous use and approved in the European Union for adult patients. It treats anaerobic bacterial infections, bacterial vaginosis, trichomoniasis, intra‑abdominal infections and pelvic inflammatory disease.

GNH USA supplies Metronidazole Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics worldwide while adhering to stringent quality standards and regulatory requirements. The company’s global logistics network ensures timely delivery across EU and other markets.

Metronidazole is an antibacterial agent used to treat infections caused by anaerobic bacteria and certain protozoa.

Anaerobic bacterial infections: eradicates infection in low‑oxygen tissues. Bacterial vaginosis: restores normal vaginal flora. Trichomoniasis: eliminates Trichomonas vaginalis infection. Intra‑abdominal infections: controls polymicrobial abdominal infections. Pelvic inflammatory disease: treats PID caused by susceptible organisms.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: upset stomach and feeling sick. - Metallic taste: persistent metallic sensation in the mouth. - Headache: mild to moderate head pain. - Abdominal discomfort: cramping or pain in the abdomen. - Diarrhea: loose stools. - Dizziness: feeling light‑headed or unsteady.

Serious or Rare Side Effects: - Seizures: convulsive episodes. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: anaphylaxis or rash. - Stevens‑Johnson syndrome: severe skin blistering. - Hepatotoxicity: liver enzyme elevation. - Neutropenia: low white‑blood‑cell count.

Use of Metronidazole requires careful consideration of several safety factors.

Pregnancy: Category B – use only if benefits outweigh risks. Liver disease: monitor hepatic function and adjust dose if needed. Alcohol interaction: avoid alcohol during treatment and for 48 hours after completion. Renal impairment: dose may need adjustment; monitor renal function. Concurrent neurotoxic drugs: increased risk of neuropathy; observe closely. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazole can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Alcohol: causes disulfiram‑like reaction. - Lithium: increased lithium toxicity. - Warfarin: enhanced anticoagulant effect. - CYP450 inducers (e.g., rifampin): reduced metronidazole levels. - CNS depressants: heightened neurotoxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise metronidazole concentrations. - Phenytoin: may lower metronidazole levels. - Carbamazepine: may reduce efficacy. - Protease inhibitors: altered metabolism. - Oral contraceptives: possible reduced effectiveness.